Darbepoetin alfa LA is under clinical development by Dong-A Socio and currently in Phase I for Anemia in Chronic Kidney Disease (Renal Anemia). According to GlobalData, Phase I drugs for Anemia in Chronic Kidney Disease (Renal Anemia) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Darbepoetin alfa LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Darbepoetin alfa LA overview
Darbepoetin alfa is a long-acting erythropoiesis-stimulating agent. It is formulated as solution for intravenous and subcutaneous route of administration. Darbepoetin alfa is indicated for the treatment of renal anemia.
Dong-A Socio overview
Dong-A Socio (Dong-A Socio Holdings), formerly Dong-A Pharmaceutical Co., Ltd, a subsidiary of Dong-A Socio Group that offers business management services. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group focuses on new business investments, APIs, OTC products, consumer goods, prescription drugs, development of biomedicines, and research and development of new innovative drugs. Its major products include quasi-drug, Bacchus; a cold medicine, Anti-inflammatory, Antipyretic, Analgesic Drug, namely, Panpyrin-T, Panpyrin Q; Morning Care; a tampon; contraceptive medicine such as Myvlar; among others. Dong-A Socio Holdings is headquartered in Seoul, South Korea.
For a complete picture of Darbepoetin alfa LA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
